(Q43273885)

18 November 2017

title

Mycophenolate mofetil for the management of steroid-refractory acute graft vs host disease (English)

1 reference

18 November 2017

J Pidala

1

1 reference

18 November 2017

J Kim

2

1 reference

18 November 2017

J Perkins

3

1 reference

18 November 2017

T Field

4

1 reference

18 November 2017

H Fernandez

5

1 reference

18 November 2017

L Perez

6

1 reference

18 November 2017

E Ayala

7

1 reference

18 November 2017

M Kharfan-Dabaja

8

1 reference

18 November 2017

C Anasetti

9

1 reference

18 November 2017

language of work or name

English

0 references

publication date

21 September 2009

1 reference

Bone Marrow Transplantation

18 November 2017

published in

1 reference

18 November 2017

volume

45

1 reference

18 November 2017

issue

5

1 reference

18 November 2017

page(s)

919-924

1 reference

https://scigraph.springernature.com/pub.10.1038/bmt.2009.252

18 November 2017

exact match

0 references

cites work

Response of 443 patients to steroids as primary therapy for acute graft-versus-host disease: comparison of grading systems

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.252

Hematopoietic stem-cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.252

Prophylaxis and treatment of acute graft-versus-host disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.252

How I treat refractory acute GVHD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.252

Treatment of steroid-resistant acute graft-versus-host disease with anti-thymocyte globulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.252

Early antithymocyte globulin therapy improves survival in patients with steroid-resistant acute graft-versus-host disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.252

A humanized non-FcR-binding anti-CD3 antibody, visilizumab, for treatment of steroid-refractory acute graft-versus-host disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.252

A phase II multicenter study of visilizumab, humanized anti-CD3 antibody, to treat steroid-refractory acute graft-versus-host disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.252

Effect of up-front daclizumab when combined with steroids for the treatment of acute graft-versus-host disease: results of a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.252

Treatment of steroid-refractory acute graft-versus-host disease with anti-CD147 monoclonal antibody ABX-CBL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.252

Response of steroid-resistant graft-versus-host disease to lymphoblast antibody CBL1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.252

A phase 2/3 multicenter randomized clinical trial of ABX-CBL versus ATG as secondary therapy for steroid-resistant acute graft-versus-host disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.252

Role of tumor necrosis factor-alpha inhibition with inflixiMAB in cancer therapy and hematopoietic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.252

Pentostatin in steroid-refractory acute graft-versus-host disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.252

Safety and efficacy of denileukin diftitox in patients with steroid-refractory acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.252

Mycophenolate mofetil for the treatment of acute and chronic GVHD in bone marrow transplant patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.252

Mycophenolate mofetil for the treatment of acute and chronic steroid-refractory graft-versus-host disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.252

Mycophenolate mofetil for the treatment of acute and chronic GVHD is effective and well tolerated but induces a high risk of infectious complications: a series of 21 BM or PBSC transplant patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.252

National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.252

Mycophenolate mofetil is effective and well tolerated in the treatment of refractory acute and chronic graft-versus-host disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.252

Different efficacy of mycophenolate mofetil as salvage treatment for acute and chronic GVHD after allogeneic stem cell transplant

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.252

Daclizumab, an efficient treatment for steroid-refractory acute graft-versus-host disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.252

inferred from DOI database lookup

7 January 2021

based on heuristic

Extracorporeal photochemotherapy for the treatment of graft-versus-host disease

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.252

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/BMT.2009.252

1 reference

Dimensions Publication ID

18 November 2017

1021109873

0 references

1 reference